Metabolomic Profiling Reveals the Potential of Fatty Acids as Regulators of Exhausted CD8 T Cells During Chronic Viral Infection
RNA-seq (gene expression) · mouse · 30 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 30 samples: 10 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE312809_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1377450 and SRA study SRP653258. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 30 samples.
How we read this: 10 replicated groups read from 30 sample titles; they account for 30 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9353870 TexSTEM, untreated, in-vivo, d21 p.i., rep1 TexSTEM, untreated, in-…
- GSM9353871 TexSTEM, untreated, in-vivo, d21 p.i., rep2 TexSTEM, untreated, in-…
- GSM9353872 TexSTEM, untreated, in-vivo, d21 p.i., rep3 TexSTEM, untreated, in-…
- GSM9353873 TexINT, untreated, in-vivo, d21 p.i., rep1 TexINT, untreated, in-v…
- GSM9353874 TexINT, untreated, in-vivo, d21 p.i., rep2 TexINT, untreated, in-v…
- GSM9353875 TexINT, untreated, in-vivo, d21 p.i., rep3 TexINT, untreated, in-v…
- GSM9353876 TexTERM, untreated, in-vivo, d21 p.i., rep1 TexTERM, untreated, in-…
- GSM9353877 TexTERM, untreated, in-vivo, d21 p.i., rep2 TexTERM, untreated, in-…
- GSM9353878 TexTERM, untreated, in-vivo, d21 p.i., rep3 TexTERM, untreated, in-…
- GSM9353879 TexSTEM, FA-treated, in-vivo, d21 p.i., rep1 TexSTEM, FA-treated, in…
- GSM9353880 TexSTEM, FA-treated, in-vivo, d21 p.i., rep2 TexSTEM, FA-treated, in…
- GSM9353881 TexSTEM, FA-treated, in-vivo, d21 p.i., rep3 TexSTEM, FA-treated, in…
- GSM9353882 TexINT, FA-treated, in-vivo, d21 p.i., rep1 TexINT, FA-treated, in-…
- GSM9353883 TexINT, FA-treated, in-vivo, d21 p.i., rep2 TexINT, FA-treated, in-…
- GSM9353884 TexINT, FA-treated, in-vivo, d21 p.i., rep3 TexINT, FA-treated, in-…
- GSM9353885 TexTERM, FA-treated, in-vivo, d21 p.i., rep1 TexTERM, FA-treated, in…
- GSM9353886 TexTERM, FA-treated, in-vivo, d21 p.i., rep2 TexTERM, FA-treated, in…
- GSM9353887 TexTERM, FA-treated, in-vivo, d21 p.i., rep3 TexTERM, FA-treated, in…
- GSM9353888 CX3CR1+, BSA only, ex-vivo, d8 p.i., rep1 CX3CR1+, BSA only, ex-v…
- GSM9353889 CX3CR1+, BSA only, ex-vivo, d8 p.i., rep2 CX3CR1+, BSA only, ex-v…
- GSM9353890 CX3CR1+, BSA only, ex-vivo, d8 p.i., rep3 CX3CR1+, BSA only, ex-v…
- GSM9353891 CX3CR1-, BSA only, ex-vivo, d8 p.i., rep1 CX3CR1-, BSA only, ex-v…
- GSM9353892 CX3CR1-, BSA only, ex-vivo, d8 p.i., rep2 CX3CR1-, BSA only, ex-v…
- GSM9353893 CX3CR1-, BSA only, ex-vivo, d8 p.i., rep3 CX3CR1-, BSA only, ex-v…
- GSM9353894 CX3CR1+, BSA-FA, ex-vivo, d8 p.i., rep1 CX3CR1+, BSA-FA, ex-viv…
- GSM9353895 CX3CR1+, BSA-FA, ex-vivo, d8 p.i., rep2 CX3CR1+, BSA-FA, ex-viv…
- GSM9353896 CX3CR1+, BSA-FA, ex-vivo, d8 p.i., rep3 CX3CR1+, BSA-FA, ex-viv…
- GSM9353897 CX3CR1-, BSA-FA, ex-vivo, d8 p.i., rep1 CX3CR1-, BSA-FA, ex-viv…
- GSM9353898 CX3CR1-, BSA-FA, ex-vivo, d8 p.i., rep2 CX3CR1-, BSA-FA, ex-viv…
- GSM9353899 CX3CR1-, BSA-FA, ex-vivo, d8 p.i., rep3 CX3CR1-, BSA-FA, ex-viv…
- GSE302682 Sleeping Beauty mutagenesis identifies BACH2 and other regulators promoting CD8+ T cell persistence and effector function under tumor-associated chronic antigen stimulation - RNAseq 66 samples shares cd8, regulators, chronic
- GSE334845 Discovery of Tcf7 regulators with clonally-resolved CRISPR screens identifies Trim28 as a mediator of CD8 T cell differentiation in tumors [RNA-Seq] 86 samples shares cd8, regulators
- GSE253492 Transcriptional Regulation by NFATc1 and NFATc2 in chronically activated CD8+ T cells 16 samples shares cd8, chronic
- GSE255887 HDAC1 controls the generation and maintenance of effector-like CD8+ T cells during chronic viral infection 76 samples shares cd8, chronic
- GSE235005 Nutrient-driven histone code determines exhausted CD8+ T cell fates [ChIP-seq] 50 samples shares cd8, exhausted
- GSE334890 Discovery of Tcf7 regulators with clonally-resolved CRISPR screens identifies Trim28 as a mediator of CD8 T cell differentiation in tumors 48 samples shares cd8, regulators
- GSE261250 Gfi1 controls the formation of effector CD8+ T cells during chronic infection and cancer 47 samples shares cd8, chronic
- GSE274865 Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy [CUT&Tag] 36 samples shares cd8, regulators
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.